Anavex Life Sciences
AVXL
#7749
Rank
ยฃ0.25 B
Marketcap
ยฃ2.91
Share price
-0.77%
Change (1 day)
-57.95%
Change (1 year)

Anavex Life Sciences (AVXL) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : ยฃ6.68 Million

According to Anavex Life Sciences 's latest financial reports the company's total liabilities are ยฃ6.68 Million. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Anavex Life Sciences - Total liabilities on balance sheet (from 2005 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-09-30ยฃ11.44 M11.34%
2023-09-30ยฃ10.27 M11.95%
2022-09-30ยฃ9.17 M14.5%
2021-09-30ยฃ8.01 M41.75%
2020-09-30ยฃ5.65 M37.92%
2019-09-30ยฃ4.1 M37.64%
2018-09-30ยฃ2.97 M11.35%
2017-09-30ยฃ2.67 M8.7%
2016-09-30ยฃ2.46 M39.91%
2015-09-30ยฃ1.75 M-60.16%
2014-09-30ยฃ4.41 M150.26%
2013-09-30ยฃ1.76 M-1.48%
2012-09-30ยฃ1.79 M107.92%
2011-09-30ยฃ0.86 M-58.85%
2010-09-30ยฃ2.09 M-21.98%
2009-09-30ยฃ2.68 M106.52%
2008-09-30ยฃ1.29 M474.2%
2007-09-30ยฃ0.22 M1412.61%
2006-09-30ยฃ0.01 M-2.4%
2005-09-30ยฃ0.01 M1000.74%
2004-09-30ยฃ0 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Ligand Pharmaceuticals
LGND
ยฃ0.39 B 5,786.44%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
ยฃ0.62 B 9,226.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Corcept Therapeutics
CORT
ยฃ0.14 B 2,042.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
ยฃ6.14 M-8.13%๐Ÿ‡บ๐Ÿ‡ธ USA